LIPO: Lipella Pharmaceuticals Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.57
Enterprise Value ($M) 2.38
Book Value ($M) 1.70
Book Value / Share 1.41
Price / Book 2.09
NCAV ($M) 1.60
NCAV / Share 1.32
Price / NCAV 2.23

Profitability (mra)
Return on Invested Capital (ROIC) -2.30
Return on Assets (ROA) -1.46
Return on Equity (ROE) -1.86

Liquidity (mrq)
Quick Ratio 4.33
Current Ratio 4.33

Balance Sheet (mrq) ($M)
Current Assets 2.08
Assets 2.18
Liabilities 0.48
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
10-17 13D/A Kaufman Jonathan H 16.20 5.60
10-17 13D/A Chancellor Michael B 16.00 0.00
02-07 13G/A Gruber Michele 5.50 3.30
01-25 13G/A Huang Leaf 9.60 0.00
01-03 13G Sabby Management, Llc 9.99

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 ☐ TRANSITION REPORT P
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 ☐ TRANSITION REPORT
2024-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-13 19,057 95,274 20.00
2024-11-12 25,155 101,745 24.72
2024-11-11 106,207 273,626 38.81
2024-11-08 309,220 944,560 32.74

(click for more detail)

Similar Companies
LEXX – Lexaria Bioscience Corp. LFVN – LifeVantage Corporation
LGVN – Longeveron Inc. LIXT – Lixte Biotechnology Holdings, Inc.
LPCN – Lipocine Inc.


Financial data and stock pages provided by
Fintel.io